Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

NCT05491525 is registered in ClinicalTrials.gov with Urovant Sciences GmbH as lead sponsor.

NCT NCT05491525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05491525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
Lead sponsor
Urovant Sciences GmbH
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 12, 2022
Completion date
September 30, 2030
Enrollment
71 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

neurogenic detrusor overactivity